Retinopathy of prematurity (ROP) is the leading cause of blindness for children, early detection and treatment can prevent ROP progression and improve the visual prognosis. ROP prevention system, including advocacy, screening, diagnosis/treatment and follow-up, is the key to reducing the rate of blindness in children. The proposed tertiary ROP prevention network includes primary health centers in county-level, secondary health centers in municipal-level and tertiary health centers in provincial-level or national-level. The idea is to explore the greatest benefits in the ROP prevention process from the existing allocation of medical resources, but also to avoid wasting at the current stage of social development. We tested this idea in Shaanxi Province recently. The preliminary practice results indicated that ROP tertiary prevention network can increase the ROP screening coverage, promote the prevention and treatment of ROP. However this work is still in its infancy. We need to expand its scope and strength the advocacy efforts to find a way to prevent and treat ROP in China.
ObjectiveTo observe clinical outcomes of laser photocoagulation on retinopathy of prematurity (ROP). MethodsClinical data of 64 cases of ROP infants (127 eyes) were studied retrospectively. Fifteen infants (30 eyes) were diagnosed of pre-threshold ROP (type Ⅰ, 23.6%) and 49 cases (97 eyes) of threshold ROP (76.4%). All the eyes underwent photocoagulation through binocular indirect ophthalmoscope (532 nm or 810 nm) within 72 hours after the confirmation ROP. In all the 15 cases (30 eyes) of pre-threshold ROP (type Ⅰ), 6 of them (12 eyes) were photocoagulated by laser of 532 nm, and the other 9 ones (18 eyes) were treated with 810 nm. In 49 threshold ROP infants (97 eyes), 37 cases (73 eyes) and 12 ones (24 eyes) were treated with laser of 532 nm or 810 nm respectively. All the infants were followed up 12-36 months (18.4 months) since photocoagulation to investigate regression of ROP. All the data of ROP infants photocoagulated, such as recovery rate of one-time photocoagulation, repeat rate, unfavorable outcomes, and complications, were analyzed statistically according to the severity of ROP and wave length of laser employed. ResultsIn all the 127 photocoagulation treated eyes, ROP regressed completely in 125 eyes (98.4%), temporal retinal traction remained in 2 eyes (1.6%), and no retinal detachment was found. ROP regressed completely in 118 eyes (92.9%) after one-time photocoagulation, recovered totally in 6 eyes (4.7%) after repeating photocoagulation 2-3 times, and resorted to cryotherapy in 3 eyes (2.4%). Subconjunctiva hemorrhage, found in 12 eyes (9.4%), was the most common complication. During photocoagulation, anesthetic accident occurred in 1 infant (1.6%), and 1 eye developed cataract (0.8%). It was suggested from statistical analysis that there was no significant difference on efficiency or safety between pre-threshold (type Ⅰ) and threshold ROP photocoagulated by laser of 532 nm or 810 nm. However, almost all of the ROP infants need repeat photocoagulation or additional cryotherapy, and patients with unfavorable outcomes or severe complications, occurred in threshold ROP treated with 532 nm laser. ConclusionPhotocoagulation with 532 nm or 810 nm laser is effective for type Ⅰ pre-threshold or threshold ROP.
ObjectiveTo observe the effect of segmental scleral buckling on the treatment of rhegmatogenous retinal detachment (RRD) with multiple retinal breaks. MethodsThis is a retrospective study. Seventeen patients (17 eyes) suffering from RRD with multiple retinal breaks were enrolled in this study. There were 8 eyes with the retinal breaks located in different quadrants and 9 eyes located in different latitudes within the same quadrant. Three were 3 eyes with 2 retinal breaks, 5 eyes with 3 retinal breaks, 9 eyes with more than 3 retinal breaks. The forms of retinal breaks included U-shaped break (4 eyes), tear break (1 eye), degenerative break (3 eyes) or U-shaped breaks combined with degenerative breaks (7 eyes), U-shaped breaks combined with tear breaks (1 eye), tear breaks combined with degenerative breaks (1 eye). The best corrected vision acuity (BCVA) was count finger to 0.8. The segmental scleral buckling was performed in all patients with the reasonable combination of silicon sponges and tires. The mean follow-up was 9.3 months (from 6 to 12 months). The BCVA, retinal attachment and complications were observed in the follow-up. ResultsFifteen eyes were reattached without recurrent of retinal detachment (88.2%). One eye with recurrent retinal detachment after 3 months due to proliferative vitreoretinopathy, and was partly reattached after vitrectomy combined with silicon oil tamponade. Retina remained detached in 2 eyes (11.8%), including 1 eye reattached after combined with gas tamponade, and 1 eye with vitrectomy. Sixteen eyes were completely reattached (94.1%), including 14 eyes were underwent only 1 operation (82.4%). The BCVA were improved more than 2 lines in 9 eyes (52.9%), 1 to 2 lines in 5 eyes (29.4%), and only 3 eyes (17.7%) without improvement. All patients have no serious complications during the operations. ConclusionFor certain patients suffering from RRD with multiple retinal breaks, a reasonable design of segmental scleral buckling can effectively increase the success rate of retinal reattachment (82.4%).
Nowadays, one of the most challenging aspects of retinoblastoma (RB) therapy is how to control the resistant or recurrent viable vitreous seeds, for which intravenous chemotherapy appears to be ineffective. Recently, intravitreal chemotherapy offers another option to control advanced stage and vitreous seeds of RB, and may be a promising new approach to RB therapy. However, intravitreal injection for RB patients raises considerable controversy due to concerns of possible extraocular extension along the injection route, and should not replace the primary standard of care for bilateral RB or group E eyes of RB. Close follow-up and further studies are needed to determine appropriate indications, to determine the effective drugs and concentrations, to optimize RB therapy protocols and to investigate the relationship between long-term efficacy and toxicities.